Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.60 |
| ▸ | AR | P10275 | 5/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24581185 | 0.80 | HRH3 (0.71) | HRH3SIGMAR1ALDH1A1 | |
| SCHEMBL24580841 | 0.79 | HRH3 (0.67) | HRH3ARSIGMAR1ALDH1A1 | |
| SCHEMBL15314493 | 0.76 | HRH3 (1.00) | HRH3ARSIGMAR1MEN1ALDH1A1 | |
| SCHEMBL450393 | 0.76 | HRH3 (1.00) | HRH3ARSIGMAR1MEN1ALDH1A1 | |
| SCHEMBL450394 | 0.76 | HRH3 (1.00) | HRH3ARSIGMAR1MEN1ALDH1A1 | |
| SCHEMBL437365 | 0.76 | HRH3 (1.00) | HRH3ARSIGMAR1MEN1ALDH1A1 | |
| SCHEMBL24564593 | 0.75 | AR (0.52) | HRH3ARSIGMAR1MEN1ALDH1A1 | |
| SCHEMBL29696971 | 0.75 | AR (0.52) | HRH3ARSIGMAR1MEN1ALDH1A1 | |
| SCHEMBL24581211 | 0.75 | HRH3 (0.67) | HRH3ARSIGMAR1MEN1ALDH1A1 | |
| SCHEMBL24581220 | 0.75 | HRH3 (0.70) | HRH3ARSIGMAR1MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022140464-A1 | COMPOUNDS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS BY TARGETING HLA-DQ2 | IMMUNOMOLECULAR THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |